The study involves patients whose lung cancer has already been treated with platinum-based chemotherapy combined with immunotherapy but has since returned. Both medications in this study will be given through intravenous infusion (delivered directly into a vein). GSK5764227 will be given at doses up to 8 milligrams per kilogram of body weight, while topotecan will be given at doses up to 1.5 milligrams per square meter of body surface area.

This is an open-label study, which means both the doctors and patients will know which treatment is being given. The treatment period may last up to 24 months, during which time doctors will monitor how well the cancer responds to the treatment and track the overall survival of patients. Throughout the study, patients will have regular check-ups to monitor their health and assess how well the treatment is working.

Tarlatamab is given through an intravenous infusion, which means it is delivered directly into a vein. The standard care medications may be given either as infusions into a vein or as oral capsules, depending on the specific medication. During treatment, doctors will monitor how well the medications work and track any changes in the cancer.

Throughout the study, healthcare providers will assess various aspects of participants’ health, including chest pain, coughing, breathing difficulties, and overall well-being. They will also monitor how the disease responds to treatment and track how long participants survive after starting treatment. The study medication or standard care will be continued as long as it provides benefit to the participant and is well tolerated.

The purpose of this study is to evaluate how well Tarlatamab works in treating patients with extensive stage small-cell lung cancer who have poor performance status and to see if this treatment is practical and manageable for these patients. The study will look at how many patients are alive after twelve months of treatment, which is the main focus of the research. It will also examine how long patients live overall, how long they live without their cancer getting worse, how many patients experience shrinkage of their tumors, and how many patients can tolerate the treatment until their first disease check-up.

During the study, patients will receive Tarlatamab treatment over a period of up to twelve months. The doctors will monitor how well the treatment works by checking if tumors shrink or disappear, including tumors that may have spread to the brain. They will also carefully watch for any side effects and assess the safety of the treatment. Additionally, the study will measure how the treatment affects patients’ quality of life and their ability to perform daily activities. The research will also track how long it takes before patients need to start a different type of cancer treatment.

The treatment involves receiving intravenous infusions of tarlatamab, which is given as a powder that is mixed into a solution before administration. The study consists of three parts, with different doses of the medication being tested. During treatment, doctors will monitor how the cancer responds to the medication and track any side effects that may occur.

Patients may continue receiving the treatment for up to 24 months, as long as their cancer does not worsen and they do not experience unacceptable side effects. Throughout the study, doctors will perform regular assessments to measure how well the treatment is working, including checking if tumors have shrunk or disappeared, how long any improvements last, and how long patients survive without their cancer getting worse.